source
- Vertex and AbCellera team up to develop next-generation T-cell engagers for autoimmune diseasesVertex Pharmaceuticals has entered a partnership with AbCellera to create next-generation T-cell engagers aimed at autoimmune diseases. AbCellera will receive an upfront payment of $28 million, wit…
- Atea's hepatitis C combo therapy shows non-inferior results to Gilead's EpclusaAtea Pharmaceuticals announced that its oral combination of bemnifosbuvir and ruzasvir met the predefined non-inferiority criteria when compared with Gilead's Epclusa for treating hepatitis C. The…